AIP
MCID: ACT029
MIFTS: 49

Acute Interstitial Pneumonia (AIP)

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Acute Interstitial Pneumonia

MalaCards integrated aliases for Acute Interstitial Pneumonia:

Name: Acute Interstitial Pneumonia 12 52 15 71
Hamman-Rich Syndrome 12 52 71
Acute Interstitial Pneumonitis 12 52
Idiopathic Pulmonary Fibrosis, Acute Fatal Form 12
Accelerated Interstitial Pneumonia 12
Idiopathic Pulmonary Fibrosis 71
Hamman-Rich Disease 12
Aip 12

Classifications:



Summaries for Acute Interstitial Pneumonia

NIH Rare Diseases : 52 Acute interstitial pneumonia (AIP) is a rare and serious condition that affects the lungs. The signs and symptoms generally develop and progress rapidly. In the early stages of the condition, affected people may experience upper respiratory and/or viral-like symptoms such as cough, shortness of breath, and fever. This is followed by the rapid onset of respiratory failure and the need for mechanical ventilation in the majority of cases. The underlying cause of AIP is unknown. Most cases occur sporadically in people with no family history of the condition. There is, unfortunately, no proven treatment for AIP. Supportive care is generally recommended to address the signs and symptoms of the condition. Glucocorticoid therapy and other immunosuppressive therapies are often used; however, the benefits of these treatments remain unclear.

MalaCards based summary : Acute Interstitial Pneumonia, also known as hamman-rich syndrome, is related to idiopathic interstitial pneumonia and adult respiratory distress syndrome, and has symptoms including dyspnea on exertion and dry cough. An important gene associated with Acute Interstitial Pneumonia is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Metabolism of proteins and Diseases of metabolism. The drugs Aztreonam and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and bone, and related phenotypes are dyspnea and pulmonary infiltrates

Disease Ontology : 12 A idiopathic interstitial pneumonia which develops suddenly and is severe. Initially, the lung shows edema, hyaline membranes, and interstitial acute inflammation. Later,it develops loose organizing fibrosis, mostly within alveolar septa and type II pneumocyte hyperplasia. Fever, cough, and difficulty breathing develop over 1 to 2 weeks, typically progressing to acute respiratory failure.

Related Diseases for Acute Interstitial Pneumonia

Diseases related to Acute Interstitial Pneumonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 idiopathic interstitial pneumonia 32.5 SFTPD SFTPC SFTPB SFTPA2
2 adult respiratory distress syndrome 30.1 SFTPD SFTPC SFTPB
3 pneumonia 30.1 SFTPD SFTPC SFTPB MUC1 CRP CD8A
4 bronchopneumonia 29.7 CRP CD8A CD4
5 pulmonary fibrosis 29.6 SFTPD SFTPC SFTPA2 ELMOD2 ABCA3
6 lipid pneumonia 29.4 SFTPB MUC1 ABCA3
7 pancytopenia 29.3 CRP CD8A CD4
8 connective tissue disease 29.2 SFTPD MUC1 CRP CD8A CD4
9 respiratory failure 29.2 SFTPD SFTPC SFTPB CRP CD4 ABCA3
10 exanthem 29.2 IFIH1 CRP CD8A CD4
11 systemic scleroderma 29.2 SFTPD CRP CD8A CD4
12 nonspecific interstitial pneumonia 29.0 SFTPD SFTPC NLRC4 MUC1 IFIH1 ABCA3
13 interstitial lung disease 28.9 SFTPD SFTPC SFTPB MUC1 IFIH1 CRP
14 pulmonary fibrosis, idiopathic 28.8 SPPL2C SFTPD SFTPC SFTPB SFTPA2 NLRC4
15 bacterial pneumonia 28.7 SFTPD SFTPB CRP CD8A CD4
16 lung disease 28.1 SFTPD SFTPC SFTPB SFTPA2 MUC1 IFIH1
17 cryptogenic organizing pneumonia 28.1 SFTPD SFTPC NLRC4 MUC1 MTUS2 CRP
18 aip familial isolated pituitary adenomas 12.6
19 porphyria, acute intermittent 12.4
20 acromegaly 12.2
21 pituitary adenoma 1, multiple types 12.2
22 autoimmune pancreatitis 12.1
23 pituitary adenoma, prolactin-secreting 12.1
24 acth-secreting pituitary adenoma 11.9
25 adenoma 11.8
26 pituitary adenoma 11.8
27 familial isolated pituitary adenoma 11.7
28 gigantism 11.6
29 acroleukopathy, symmetric 11.6
30 pituitary tumors 11.6
31 porphyria 11.6
32 pituitary apoplexy 11.6
33 autoimmune pancreatitis type 1 11.6
34 hormone producing pituitary cancer 11.5
35 multiple endocrine neoplasia, type i 11.5
36 inherited cancer-predisposing syndrome 11.5
37 carney complex variant 11.5
38 growth hormone secreting pituitary adenoma 11.4
39 hepatitis b 11.4
40 multiple endocrine neoplasia, type iv 11.4
41 functioning pituitary adenoma 11.4
42 hepatitis 11.4
43 chester porphyria 11.3
44 autoimmune pancreatitis type 2 11.2
45 cell type benign neoplasm 11.1
46 endocrine organ benign neoplasm 11.1
47 pituitary infarct 11.1
48 hyperpituitarism 11.1
49 pituitary carcinoma 11.1
50 pituitary gland disease 11.1

Graphical network of the top 20 diseases related to Acute Interstitial Pneumonia:



Diseases related to Acute Interstitial Pneumonia

Symptoms & Phenotypes for Acute Interstitial Pneumonia

Human phenotypes related to Acute Interstitial Pneumonia:

31 (show all 32)
# Description HPO Frequency HPO Source Accession
1 dyspnea 31 hallmark (90%) HP:0002094
2 pulmonary infiltrates 31 hallmark (90%) HP:0002113
3 respiratory failure 31 hallmark (90%) HP:0002878
4 hypoxemia 31 hallmark (90%) HP:0012418
5 bronchiectasis 31 hallmark (90%) HP:0002110
6 ground-glass opacification on pulmonary hrct 31 hallmark (90%) HP:0025179
7 peribronchovascular interstitial thickening 31 hallmark (90%) HP:0025177
8 nodular pattern on pulmonary hrct 31 hallmark (90%) HP:0025392
9 reticulonodular pattern on pulmonary hrct 31 hallmark (90%) HP:0025393
10 interlobular septal thickening on pulmonary hrct 31 hallmark (90%) HP:0030879
11 fatigue 31 frequent (33%) HP:0012378
12 fever 31 frequent (33%) HP:0001945
13 hypertension 31 frequent (33%) HP:0000822
14 tachypnea 31 frequent (33%) HP:0002789
15 cyanosis 31 frequent (33%) HP:0000961
16 pleural effusion 31 frequent (33%) HP:0002202
17 crackles 31 frequent (33%) HP:0030830
18 nonproductive cough 31 frequent (33%) HP:0031246
19 decreased dlco 31 frequent (33%) HP:0045051
20 arthralgia 31 occasional (7.5%) HP:0002829
21 pulmonary fibrosis 31 occasional (7.5%) HP:0002206
22 myalgia 31 occasional (7.5%) HP:0003326
23 chest pain 31 occasional (7.5%) HP:0100749
24 atelectasis 31 occasional (7.5%) HP:0100750
25 lymphadenopathy 31 occasional (7.5%) HP:0002716
26 elevated c-reactive protein level 31 occasional (7.5%) HP:0011227
27 elevated erythrocyte sedimentation rate 31 occasional (7.5%) HP:0003565
28 pericardial effusion 31 occasional (7.5%) HP:0001698
29 peripheral edema 31 occasional (7.5%) HP:0012398
30 elevated serum creatinine 31 occasional (7.5%) HP:0003259
31 subpleural honeycombing 31 occasional (7.5%) HP:0031631
32 reduced hematocrit 31 occasional (7.5%) HP:0031851

UMLS symptoms related to Acute Interstitial Pneumonia:


dyspnea on exertion, dry cough

Drugs & Therapeutics for Acute Interstitial Pneumonia

Drugs for Acute Interstitial Pneumonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5742832 5362041
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Nintedanib Approved Phase 4 656247-17-5 56843413
4 lysine Phase 4
5 Immunoglobulins Phase 4
6 Antibodies Phase 4
7 Anti-Inflammatory Agents Phase 4
8 Hormones Phase 4
9 Hormone Antagonists Phase 4
10 Antineoplastic Agents, Hormonal Phase 4
11 glucocorticoids Phase 4
12
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
13
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
14
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
15
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
16
Pirfenidone Approved, Investigational Phase 3 53179-13-8 40632
17
leucovorin Approved Phase 3 58-05-9 6006 143
18
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
19
Morphine Approved, Investigational Phase 3 57-27-2 5288826
20
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
21
Azathioprine Approved Phase 3 446-86-6 2265
22
Sulfamethoxazole Approved Phase 3 723-46-6 5329
23
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
24
Losartan Approved Phase 2, Phase 3 114798-26-4 3961
25
Angiotensin II Approved, Investigational Phase 2, Phase 3 4474-91-3, 11128-99-7, 68521-88-0 172198
26
Warfarin Approved Phase 3 81-81-2 6691 54678486
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
28
Cysteine Approved, Nutraceutical Phase 3 52-90-4 5862
29 Platelet Aggregation Inhibitors Phase 2, Phase 3
30 Rho(D) Immune Globulin Phase 3
31 Immunoglobulins, Intravenous Phase 3
32 gamma-Globulins Phase 3
33 Protein Kinase Inhibitors Phase 2, Phase 3
34 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
35 Immunoglobulin G Phase 3
36 Antilymphocyte Serum Phase 3
37 Analgesics Phase 3
38 Analgesics, Non-Narcotic Phase 3
39 Antirheumatic Agents Phase 3
40 Anti-Inflammatory Agents, Non-Steroidal Phase 3
41 Vitamin B Complex Phase 3
42 Folate Phase 3
43 Vitamin B9 Phase 3
44 Adrenergic alpha-Antagonists Phase 2, Phase 3
45 Excitatory Amino Acid Antagonists Phase 2, Phase 3
46 Adrenergic Agents Phase 2, Phase 3
47 Adrenergic Antagonists Phase 2, Phase 3
48 Neurotransmitter Agents Phase 2, Phase 3
49 Narcotics Phase 3
50 Analgesics, Opioid Phase 3

Interventional clinical trials:

(show top 50) (show all 415)
# Name Status NCT ID Phase Drugs
1 Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Unknown status NCT01382368 Phase 4 Sildenafil
2 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
3 Pirfenidone for Progressive Fibrotic Sarcoidosis Unknown status NCT03260556 Phase 4 Pirfenidone;Placebos
4 Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study. Unknown status NCT00637065 Phase 4 Bosentan;Placebo
5 Digital Auscultation Tool - Development of an Innovative Approach - Using Modern Technologies - to Improve the Diagnosis of Rare Lung Diseases - Expanded Data Collection Idiopathic Pulmonary Fibrosis Completed NCT03503188 Phase 4
6 An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis Completed NCT02598193 Phase 4 Nintedanib;Pirfenidone
7 A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT02579603 Phase 4 Nintedanib;Pirfenidone
8 A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment. Completed NCT02788474 Phase 4 nintedanib;placebo
9 Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study) Completed NCT02606877 Phase 4 nintedanib;pirfenidone
10 Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
11 Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL Recruiting NCT03717012 Phase 4 Nintedanib
12 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Recruiting NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
13 Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial Not yet recruiting NCT03939520 Phase 4 pirfenidone and nintedanib;pirfenidone or nintedanib
14 Employment of 68Ga-DOTA-NOC in Patients With Idiopathic Pulmonary Fibrosis Terminated NCT01321996 Phase 4
15 Randomized Placebo-Controlled Study of Sildenafil For The Treatment of Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis: A Pilot Study Withdrawn NCT00625079 Phase 4 sildenafil
16 Treatment of Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Hypertension With Bosentan: A Single Center Pilot Study Withdrawn NCT00625469 Phase 4 bosentan
17 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
18 Inhaled Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis Unknown status NCT00439543 Phase 2, Phase 3 Iloprost inhalation
19 A Randomized, Double-blinded, Placebo Controlled Study to Evaluate Clinical Efficacy and Safety of Pirfenidone for Skin Fibrosis in Systemic Sclerosis Unknown status NCT03068234 Phase 2, Phase 3 Pirfenidone;Placebo oral capsule;Steroids
20 INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment Completed NCT02802345 Phase 3 Nintedanib;Placebo;Sildenafil
21 Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443) Completed NCT00631475 Phase 3 Bosentan
22 Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00639496 Phase 3 n-acetylcysteine;placebo
23 Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study. Completed NCT00391443 Phase 3 Bosentan;Placebo
24 A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (ASCEND Trial) Completed NCT01366209 Phase 3 Pirfenidone;Placebo
25 Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123 Completed NCT02739165 Phase 3 ART-123;Placebo
26 Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice Completed NCT03208933 Phase 3 Pirfenidone
27 A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00047645 Phase 3 Interferon-gamma 1b
28 A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287729 Phase 3 Pirfenidone;Placebo
29 A Randomized, Double-Blind, Placebo Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00287716 Phase 3 Pirfenidone;Placebo
30 A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis, Open Label Extension Completed NCT00071461 Phase 2, Phase 3 bosentan;Placebo
31 An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT00662038 Phase 3 pirfenidone
32 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide Completed NCT00600028 Phase 3 Thalidomide;Placebo
33 Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial Completed NCT02460588 Phase 3 Cyclophosphamide;Placebo;Corticosteroid (prednisolone)
34 A Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy (Gleevec Imatinib Mesylate) in Patients With Idiopathic Pulmonary Fibrosis Completed NCT00131274 Phase 2, Phase 3 Imatinib Mesylate (Gleevec)
35 A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
36 A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01335477 Phase 3 placebo;BIBF 1120
37 A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF) Completed NCT01335464 Phase 3 placebo;BIBF 1120
38 Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF Completed NCT00650091 Phase 3 N-acetylcysteine (NAC);Placebo
39 Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Completed NCT00517933 Phase 3 Sildenafil Citrate
40 Pharmacokinetics of Mycophenolate Mofetil in de Novo Lung Allograft Recipients Completed NCT01014442 Phase 3 mycophenolate mofetil
41 A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Completed NCT02999178 Phase 3 Nintedanib;Placebo
42 A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Completed NCT02597933 Phase 3 Nintedanib;Placebo
43 A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) Completed NCT00105183 Phase 3
44 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
45 A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis Recruiting NCT03711162 Phase 3 GLPG1690;Placebo
46 A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis Recruiting NCT03733444 Phase 3 GLPG1690;Placebo
47 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Recruiting NCT03955146 Phase 3 Pamrevlumab;Placebo
48 A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2 Recruiting NCT03283007 Phase 3 Nintedanib;Placebo
49 A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection Recruiting NCT04282902 Phase 3 pirfenidone
50 An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Active, not recruiting NCT01619085 Phase 3 BIBF 1120

Search NIH Clinical Center for Acute Interstitial Pneumonia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


nintedanib

Genetic Tests for Acute Interstitial Pneumonia

Anatomical Context for Acute Interstitial Pneumonia

MalaCards organs/tissues related to Acute Interstitial Pneumonia:

40
Lung, Testes, Bone, Bone Marrow, Skeletal Muscle, Liver, Endothelial

Publications for Acute Interstitial Pneumonia

Articles related to Acute Interstitial Pneumonia:

(show top 50) (show all 520)
# Title Authors PMID Year
1
Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. 61
32277367 2020
2
Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome. 61
32447116 2020
3
The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. 61
32434133 2020
4
Acute interstitial pneumonia triggered by strenuous exercise. 61
32382496 2020
5
Resecting a giant malignant lung tumor in a patient with unilateral acute interstitial pneumonitis. 61
32156474 2020
6
Radiological patterns of drug induced interstitial lung disease (DILD) in early phase oncology clinical trials. 61
32332017 2020
7
Outbreak of COVID-19 infection in children: fear and serenity. 61
32373997 2020
8
Outbreak investigation of septicemic salmonellosis in calves. 61
32088691 2020
9
Lesions Observed Post Mortem in Post-hatchling Loggerhead Sea Turtles (Caretta caretta) from a Head Start Programme. 61
31955806 2020
10
Time-course transcriptomic alterations reflect the pathophysiology of polyhexamethylene guanidine phosphate-induced lung injury in rats. 61
31971030 2019
11
Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. 61
31584861 2019
12
Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: Clinical and radiologic characteristics and risk factors. 61
31770246 2019
13
Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 1. Introduction. 61
31172699 2019
14
Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma. 61
31020569 2019
15
Molecular hydrogen attenuates gefitinib-induced exacerbation of naphthalene-evoked acute lung injury through a reduction in oxidative stress and inflammation. 61
30710119 2019
16
Incidental tracheal bronchus in a case of Hamman-Rich syndrome. 61
31092498 2019
17
An Elusive Case of Acute Interstitial Pneumonia. 61
31333914 2019
18
Up-regulation of THY1 attenuates interstitial pulmonary fibrosis and promotes lung fibroblast apoptosis during acute interstitial pneumonia by blockade of the WNT signaling pathway. 61
30829553 2019
19
Staphylococcus pseudintermedius septicemia in puppies after elective cesarean section: confirmed transmission via dam's milk. 61
30691457 2019
20
Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases. 61
31839671 2019
21
Pneumocystis jirovecii infection in patients with acute interstitial pneumonia. 61
29891174 2018
22
Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification. 61
30369660 2018
23
Clinical presentation and pathology of suspected vector transmitted African horse sickness in South African domestic dogs from 2006 to 2017. 61
29519857 2018
24
Extracorporeal Membrane Oxygenation for Refractory Severe Respiratory Failure in Acute Interstitial Pneumonia. 61
29323413 2018
25
Respiratory Mites ( Orthohalarachne diminuata) and β-hemolytic Streptococci-Associated Bronchopneumonia Outbreak in South American Fur Seal Pups ( Arctocephalus australis). 61
29369727 2018
26
Acute interstitial pneumonia as first presentation of anti-synthetase syndrome: an atypical case. 61
29644083 2018
27
Time course of polyhexamethyleneguanidine phosphate-induced lung inflammation and fibrosis in mice. 61
29476863 2018
28
Preliminary evidence that hydrostatic edema may contribute to the formation of diffuse alveolar damage in a Holstein calf model. 61
30555684 2018
29
Hamman-Rich syndrome. 61
29159034 2018
30
Acute respiratory failure due to diffuse parenchymal lung diseases in a respiratory intensive care unit of North India. 61
32476924 2018
31
Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. 61
29293605 2018
32
[Efficacy and safety of transbronchial cryobiopsy in the etiologic diagnosis of diffuse lung disease]. 61
29275603 2017
33
[Clinical features of acute diffuse pulmonary exudative disorders]. 61
29275576 2017
34
Abruptio Placentae with Type II Respiratory Failure Secondary to Acute Interstitial Pneumonia Responsive to Steroids. 61
28969741 2017
35
[Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography]. 61
28872085 2017
36
A 45-Year-Old Woman with Acute Interstitial Pneumonia (Hamman-Rich Syndrome). 61
28868178 2017
37
Hamman-Rich syndrome: a forgotten entity. 61
28635201 2017
38
Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer). 61
28158568 2017
39
[Unusual histopathological picture of acute lung injury in different stages of resorption with predominance of organizing pneumonia in a young man with influenza A (H1N1)]. 61
28248121 2017
40
Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion. 61
31149466 2017
41
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. 61
27535979 2016
42
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. 61
27733144 2016
43
Severe Toxocariasis in Children-Diagnostic Difficulties. 61
30581597 2016
44
High-resolution CT findings of idiopathic pneumonia syndrome after haematopoietic stem cell transplantation: based on the updated concept of idiopathic pneumonia syndrome by the American Thoracic Society in 2011. 61
27421574 2016
45
Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis. 61
27307530 2016
46
Genetic parameters estimated at receiving for circulating cortisol, immunoglobulin G, interleukin 8, and incidence of bovine respiratory disease in feedlot beef steers. 61
27482664 2016
47
Acute and subacute idiopathic interstitial pneumonias. 61
27123874 2016
48
Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer. 61
28006019 2016
49
Primary Sjogren's Syndrome Presenting as Acute Interstitial Pneumonitis/Hamman-Rich Syndrome. 61
27818685 2016
50
American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. 61
26452110 2015

Variations for Acute Interstitial Pneumonia

Expression for Acute Interstitial Pneumonia

Search GEO for disease gene expression data for Acute Interstitial Pneumonia.

Pathways for Acute Interstitial Pneumonia

Pathways related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 TBCB SFTPD SFTPC SFTPB SFTPA2 MUC1
2
Show member pathways
11.43 SFTPD SFTPC SFTPB SFTPA2
3 11.23 SFTPC SFTPA2 ELMOD2
4
Show member pathways
10.65 SFTPD SFTPC SFTPB SFTPA2
5
Show member pathways
10.65 SFTPD SFTPC SFTPB SFTPA2 ABCA3

GO Terms for Acute Interstitial Pneumonia

Cellular components related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.95 SFTPD SFTPC SFTPB SFTPA2 MUC1 CRP
2 endoplasmic reticulum membrane GO:0005789 9.85 SPPL2C SFTPD SFTPC SFTPB SFTPA2 CD4
3 multivesicular body GO:0005771 9.43 SFTPD SFTPB SFTPA2
4 lamellar body GO:0042599 9.33 SFTPC SFTPB SFTPA2
5 multivesicular body lumen GO:0097486 9.32 SFTPC SFTPB
6 alveolar lamellar body GO:0097208 9.13 SFTPC SFTPB ABCA3
7 clathrin-coated endocytic vesicle GO:0045334 8.92 SFTPD SFTPC SFTPB SFTPA2

Biological processes related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.55 SFTPD NLRC4 IFIH1 CD8A CD4
2 cellular protein metabolic process GO:0044267 9.35 SFTPD SFTPC SFTPB SFTPA2 ABCA3
3 respiratory gaseous exchange GO:0007585 8.92 SFTPD SFTPC SFTPB SFTPA2

Molecular functions related to Acute Interstitial Pneumonia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 SFTPD SFTPC NLRC4 IFIH1 CRP CD4
2 monosaccharide binding GO:0048029 8.62 SFTPD SFTPA2

Sources for Acute Interstitial Pneumonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....